Skip to main content

Advertisement

Log in

GLOMERULAR DISEASE

CUBN variants uncouple proteinuria from kidney function

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

A new study links pathogenic cubilin gene (CUBN) variants to proteinuria without progressive renal impairment, providing reassurance for a subset of patients, calling into question the accepted pathogenesis of glomerulosclerosis and suggesting future therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Potential use of cubilin blockade to reduce progressive proteinuric kidney impairment.

References

  1. Roscioni, S. S., Heerspink, H. J. L. & de Zeeuw, D. Microalbuminuria: target for renoprotective therapy PRO. Kidney Int. 86, 40–49 (2014).

    Article  CAS  Google Scholar 

  2. Bedin, M. et al. Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function. J. Clin. Invest. https://doi.org/10.1172/JCI129937 (2019).

    Article  Google Scholar 

  3. Jayasinghe, K. et al. Isolated proteinuria due to CUBN homozygous mutation – challenging the investigative paradigm. BMC Nephrol. 20, 330 (2019).

    Article  Google Scholar 

  4. Kashtan, C. E. et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr. Nephrol. 28, 5–11 (2013).

    Article  Google Scholar 

  5. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).

    Article  CAS  Google Scholar 

  6. Dickson, L. E. et al. The proximal tubule and albuminuria: really! J. Am. Soc. Nephrol. 25, 443–453 (2014).

    Article  CAS  Google Scholar 

  7. Amsellem, S. et al. Cubilin is essential for albumin reabsorption in the renal proximal tubule. J. Am. Soc. Nephrol. 21, 1859–1867 (2010).

    Article  CAS  Google Scholar 

  8. Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).

    Article  CAS  Google Scholar 

  9. Trachtman, H. et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 29, 2745–2754 (2018).

    Article  CAS  Google Scholar 

  10. Simons, M. The benefits of tubular proteinuria: an evolutionary perspective. J. Am. Soc. Nephrol. 29, 710–712 (2018).

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The author is supported by the Royal Children’s Hospital Foundation, Melbourne Genomics Health Alliance, the KidGen Collaborative and the Australian Genomics Health Alliance. The Murdoch Children’s Research Institute is supported by the Victorian Government’s Operational Infrastructure Support Program.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Catherine Quinlan.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quinlan, C. CUBN variants uncouple proteinuria from kidney function. Nat Rev Nephrol 16, 135–136 (2020). https://doi.org/10.1038/s41581-019-0242-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-019-0242-4

  • Springer Nature Limited

Navigation